NO2017056I2 - glekaprevir eller et farmasøytisk akseptabelt salt eller en ester derav - Google Patents

glekaprevir eller et farmasøytisk akseptabelt salt eller en ester derav

Info

Publication number: NO2017056I2
Authority: NO; Norway
Prior art keywords: glaucoma; virus; ester; pharmaceutically acceptable; acceptable salt
Prior art date: 2010-09-21

Application number

NO2017056C

Other languages

English (en)

Other versions

NO2017056I1 (no

Original Assignee

Enanta Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-21

Filing date

2017-11-10

Publication date

2018-11-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45817947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2017056(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-11-10 Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc

2017-11-10 Publication of NO2017056I1 publication Critical patent/NO2017056I1/no

2018-11-26 Publication of NO2017056I2 publication Critical patent/NO2017056I2/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/123—Tripeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Virology (AREA)
Mycology (AREA)
Microbiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO2017056C 2010-09-21 2017-11-10 glekaprevir eller et farmasøytisk akseptabelt salt eller en ester derav NO2017056I2 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US38505810P	2010-09-21	2010-09-21
US201161499994P	2011-06-22	2011-06-22
US201161504616P	2011-07-05	2011-07-05
PCT/US2011/052304 WO2012040167A1 (en)	2010-09-21	2011-09-20	Macrocyclic proline derived hcv serine protease inhibitors

Publications (2)

Publication Number	Publication Date
NO2017056I1 NO2017056I1 (no)	2017-11-10
NO2017056I2 true NO2017056I2 (no)	2018-11-26

Family

ID=45817947

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO2017056C NO2017056I2 (no)	2010-09-21	2017-11-10	glekaprevir eller et farmasøytisk akseptabelt salt eller en ester derav
NO2021040C NO2021040I1 (no)	2010-09-21	2021-09-16	glecaprevir or a pharmaceutically acceptable salt or ester thereof- forlenget SPC

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2021040C NO2021040I1 (no)	2010-09-21	2021-09-16	glecaprevir or a pharmaceutically acceptable salt or ester thereof- forlenget SPC

Country Status (42)

Country	Link
US (7)	US8648037B2 (no)
EP (2)	EP3020723A1 (no)
JP (5)	JP5857053B2 (no)
KR (5)	KR102128232B1 (no)
CN (2)	CN104829688B (no)
AR (1)	AR083052A1 (no)
AU (2)	AU2011305695B2 (no)
BR (1)	BR112013006693B1 (no)
CA (1)	CA2812261C (no)
CL (2)	CL2013000791A1 (no)
CO (1)	CO6700835A2 (no)
CR (2)	CR20180517A (no)
CY (2)	CY1117113T1 (no)
DK (1)	DK2618831T3 (no)
DO (2)	DOP2013000062A (no)
EA (2)	EA023009B1 (no)
EC (2)	ECSP13012559A (no)
ES (1)	ES2560003T3 (no)
GT (2)	GT201300077A (no)
HK (2)	HK1223955A1 (no)
HR (1)	HRP20160083T1 (no)
HU (2)	HUE028384T2 (no)
IL (1)	IL225412A (no)
LT (1)	LTC2618831I2 (no)
LU (1)	LUC00037I2 (no)
MX (3)	MX343275B (no)
MY (1)	MY164754A (no)
NL (1)	NL300900I2 (no)
NO (2)	NO2017056I2 (no)
NZ (2)	NZ608720A (no)
PE (1)	PE20140015A1 (no)
PL (1)	PL2618831T3 (no)
PT (1)	PT2618831E (no)
RS (1)	RS54638B1 (no)
SG (1)	SG188618A1 (no)
SI (1)	SI2618831T1 (no)
SM (1)	SMT201600100B (no)
TW (1)	TWI523658B (no)
UA (1)	UA116616C2 (no)
UY (2)	UY38339A (no)
WO (1)	WO2012040167A1 (no)
ZA (2)	ZA201302317B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2011012155A (es) *	2009-05-13	2012-02-28	Enanta Pharm Inc	Compuestos macrociclicos como inhibidores del virus de hepatitis c.
TW201119667A (en) *	2009-10-19	2011-06-16	Enanta Pharm Inc	Bismacrocyclic compounds as hepatitis C virus inhibitors
CN104829688B (zh)	2010-09-21	2021-02-09	益安药业	大环脯氨酸衍生的hcv丝氨酸蛋白酶抑制剂
US8957203B2 (en)	2011-05-05	2015-02-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
UA119315C2 (uk)	2012-07-03	2019-06-10	Гіліад Фармассет Елелсі	Інгібітори вірусу гепатиту с
MX360452B (es)	2012-10-19	2018-11-01	Bristol Myers Squibb Co	Inhibidores del virus de la hepatitis c.
EP2914613B1 (en)	2012-11-02	2017-11-22	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US9643999B2 (en)	2012-11-02	2017-05-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2914598B1 (en)	2012-11-02	2017-10-18	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US9409943B2 (en)	2012-11-05	2016-08-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2014137869A1 (en)	2013-03-07	2014-09-12	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
WO2014152514A1 (en) *	2013-03-14	2014-09-25	Abbvie Inc.	Combination of two antivirals for treating hepatitis c
US20180042982A1 (en) *	2013-03-14	2018-02-15	Abbvie Inc.	Methods for Treating HCV
CN108187056A (zh)	2013-03-14	2018-06-22	艾伯维公司	用于治疗hcv患者的直接作用的抗病毒剂和利巴韦林的组合
US20200368229A9 (en) *	2013-03-14	2020-11-26	Abbvie Inc.	Methods for Treating HCV
MX2015013224A (es)	2013-03-15	2015-12-11	Gilead Sciences Inc	Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
CA2925328A1 (en) *	2013-10-25	2015-04-30	Abbvie, Inc.	Methods for treating hcv
NZ720745A (en)	2013-12-23	2018-02-23	Gilead Sciences Inc	Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide
NZ720887A (en) *	2013-12-23	2018-01-26	Gilead Sciences Inc	Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
EP2899207A1 (en)	2014-01-28	2015-07-29	Amikana.Biologics	New method for testing HCV protease inhibition
CN112704726A (zh) *	2014-04-02	2021-04-27	艾伯维公司	治疗hcv的方法
MX2016012722A (es) *	2014-04-02	2016-12-16	Abbvie Inc	Metodos para tratar el virus de la hepatitis c.
US9321807B2 (en)	2014-06-06	2016-04-26	Abbvie Inc.	Crystal forms
TWI721947B (zh)	2014-06-11	2021-03-21	美商基利法瑪席特有限責任公司	抗病毒化合物的固態形式
US9809576B1 (en)	2014-07-18	2017-11-07	Abbvie Inc.	Synthetic route to anti-viral agents
US9809534B1 (en)	2014-07-21	2017-11-07	Abbvie Inc.	Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof
US10059969B1 (en)	2014-10-03	2018-08-28	Abbvie Inc.	Process for the preparation of (S)-2-amino-non-8-enoic acid
US10316338B1 (en)	2015-01-30	2019-06-11	Abb Vie Inc.	Enzymatic process for the preparation of (1S,2R)-2-(difluoromethyl)-1-(propoxycarbonyl)cyclopropanecarboxylic acid
WO2016134058A1 (en)	2015-02-18	2016-08-25	Abbvie Inc.	Combinations useful to treat hepatitis c virus
US20160375017A1 (en)	2015-06-26	2016-12-29	Abbvie Inc.	Solid Pharmaceutical Compositions for Treating HCV
US20160375087A1 (en) *	2015-06-26	2016-12-29	Abbvie Inc.	Solid Pharmaceutical Compositions for Treating HCV
EP3319604A1 (en)	2015-07-08	2018-05-16	AbbVie Inc.	Methods for treating hcv
KR20240108528A (ko)	2015-07-17	2024-07-09	애브비 인코포레이티드	Hcv의 치료를 위한 고형 약제학적 조성물
KR101726567B1 (ko)	2016-07-08	2017-04-13	박공영	수직형 식물 재배장치
JP2020505952A (ja)	2017-02-01	2020-02-27	アッヴィ・インコーポレイテッド	（±）−２−（ジフルオロメチル）−１−（アルコキシカルボニル）シクロプロパンカルボン酸及び（±）−２−（ビニル）−１−（アルコキシカルボニル）シクロプロパンカルボン酸の酵素的製造方法
JP2018131439A (ja)	2017-02-14	2018-08-23	アッヴィ・インコーポレイテッド	Ｈｃｖを処置する方法
CA2981993A1 (en)	2017-08-02	2019-02-02	Abbvie Inc.	Methods for treating hcv
WO2019046569A1 (en) *	2017-09-01	2019-03-07	Abbvie Inc.	METHODS FOR THE TREATMENT OF HCV
WO2019074507A1 (en)	2017-10-12	2019-04-18	Abbvie Inc.	METHODS FOR THE TREATMENT OF HCV
WO2019084740A1 (zh) *	2017-10-31	2019-05-09	上海同昌生物医药科技有限公司	一种Glecaprevir合成中间体及其胺盐的制备方法
CN107739319A (zh) *	2017-10-31	2018-02-27	上海同昌生物医药科技有限公司	一种Glecaprevir合成中间体及其胺盐的制备方法
CN108329332A (zh) *	2018-03-16	2018-07-27	安徽华昌高科药业有限公司	一种制备Glecaprevir的方法
KR20210150501A (ko)	2019-04-08	2021-12-10	애브비 인코포레이티드	Hcv를 치료하기 위한 고체 약제학적 조성물
KR102681664B1 (ko)	2019-06-12	2024-07-05	엘지디스플레이 주식회사	폴더블 디스플레이와 그 구동 방법
WO2021137256A1 (en)	2020-01-03	2021-07-08	Mylan Laboratories Limited	Polymorphic forms of glecaprevir
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en)	2020-10-28	2024-09-10	Accencio LLC	Methods of treating symptoms of coronavirus infection with viral protease inhibitors
CN114085458A (zh) *	2021-12-08	2022-02-25	宁波塑之华塑化有限公司	一种高强度高韧性阻燃聚丙烯复合材料及其制备方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6143715A (en)	1997-08-11	2000-11-07	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C inhibitor peptide analogues
ES2241157T3 (es)	1997-08-11	2005-10-16	Boehringer Ingelheim (Canada) Ltd.	Peptidos inhibidores de la hepatitis c.
IL138037A0 (en)	1998-02-25	2001-10-31	Univ Emory	2'-fluoronucleosides
US6323180B1 (en)	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
AR022061A1 (es)	1998-08-10	2002-09-04	Boehringer Ingelheim Ca Ltd	Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
UA74546C2 (en) *	1999-04-06	2006-01-16	Boehringer Ingelheim Ca Ltd	Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
AU1262001A (en)	1999-11-04	2001-05-14	Biochem Pharma Inc.	Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
RU2223761C2 (ru)	1999-12-27	2004-02-20	Джапан Тобакко Инк.	Соединения с конденсированным кольцом и их использование в качестве лекарственных средств
NZ521210A (en)	2000-02-18	2004-11-26	Shire Biochem Inc	Method for the treatment or prevention of flavivirus infections using nucleoside analogues
EP1268525B1 (en)	2000-04-05	2008-12-31	Schering Corporation	Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
US6448281B1 (en)	2000-07-06	2002-09-10	Boehringer Ingelheim (Canada) Ltd.	Viral polymerase inhibitors
JP3889708B2 (ja)	2000-11-20	2007-03-07	ブリストル−マイヤーズスクイブカンパニー	Ｃ型肝炎トリペプチド阻害剤
AR035543A1 (es)	2001-06-26	2004-06-16	Japan Tobacco Inc	Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003007945A1 (en)	2001-07-20	2003-01-30	Boehringer Ingelheim (Canada) Ltd.	Viral polymerase inhibitors
EP2335700A1 (en)	2001-07-25	2011-06-22	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C virus polymerase inhibitors with a heterobicylic structure
EP1429759A4 (en)	2001-09-26	2004-12-15	Bristol Myers Squibb Co	COMPOUNDS FOR TREATING HEPATITIS C VIRUS
US6867185B2 (en)	2001-12-20	2005-03-15	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
CA2369711A1 (en)	2002-01-30	2003-07-30	Boehringer Ingelheim (Canada) Ltd.	Macrocyclic peptides active against the hepatitis c virus
CA2370396A1 (en)	2002-02-01	2003-08-01	Boehringer Ingelheim (Canada) Ltd.	Hepatitis c inhibitor tri-peptides
CA2369970A1 (en)	2002-02-01	2003-08-01	Boehringer Ingelheim (Canada) Ltd.	Hepatitis c inhibitor tri-peptides
ATE413411T1 (de)	2002-05-20	2008-11-15	Bristol Myers Squibb Co	Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
AU2003248535A1 (en)	2002-05-20	2003-12-12	Bristol-Myers Squibb Company	Heterocyclicsulfonamide hepatitis c virus inhibitors
WO2004032827A2 (en)	2002-05-20	2004-04-22	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
JP4602076B2 (ja)	2002-06-04	2010-12-22	ネオジェネシスファーマシューティカルズインコーポレイテッド	抗ウイルス剤としてのピラゾロ［１，５ａ］ピリミジン化合物
US20040138109A1 (en)	2002-09-30	2004-07-15	Boehringer Ingelheim Pharmaceuticals, Inc.	Potent inhibitor of HCV serine protease
US20050075279A1 (en)	2002-10-25	2005-04-07	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis C virus
US20050159345A1 (en)	2002-10-29	2005-07-21	Boehringer Ingelheim International Gmbh	Composition for the treatment of infection by Flaviviridae viruses
US7223785B2 (en)	2003-01-22	2007-05-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US7098231B2 (en)	2003-01-22	2006-08-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
WO2004072243A2 (en)	2003-02-07	2004-08-26	Enanta Pharmaceuticals, Inc.	Macrocyclic hepatitis c serine protease inhibitors
WO2004101605A1 (en)	2003-03-05	2004-11-25	Boehringer Ingelheim International Gmbh	Hepatitis c inhibiting compounds
ES2354282T3 (es)	2003-03-05	2011-03-11	Boehringer Ingelheim International Gmbh	Análogos peptídicos inhibidores de la hepatitis c.
GB0307891D0 (en)	2003-04-04	2003-05-14	Angeletti P Ist Richerche Bio	Chemical compounds,compositions and uses
US7173004B2 (en)	2003-04-16	2007-02-06	Bristol-Myers Squibb Company	Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
ES2535147T3 (es)	2003-04-18	2015-05-06	Enanta Pharmaceuticals, Inc.	Compuestos macrocíclicos de quinoxalinilo que inhiben las serina proteasas de la hepatitis C
US7176208B2 (en)	2003-04-18	2007-02-13	Enanta Pharmaceuticals, Inc.	Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
WO2004103996A1 (en)	2003-05-21	2004-12-02	Boehringer Ingelheim International Gmbh	Hepatitis c inhibitor compounds
WO2004113365A2 (en)	2003-06-05	2004-12-29	Enanta Pharmaceuticals, Inc.	Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en)	2003-07-03	2006-10-24	Enanta Pharmaceuticals, Inc.	Aza-peptide macrocyclic hepatitis C serine protease inhibitors
AU2004261667A1 (en)	2003-08-01	2005-02-10	Genelabs Technologies, Inc.	Bicyclic imidazol derivatives against Flaviviridae
WO2005014543A1 (ja)	2003-08-06	2005-02-17	Japan Tobacco Inc.	縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
AU2004274051A1 (en)	2003-09-22	2005-03-31	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis C virus
CA2540858C (en)	2003-10-14	2009-12-08	Intermune, Inc.	Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7132504B2 (en)	2003-11-12	2006-11-07	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JPWO2005049622A1 (ja)	2003-11-19	2007-06-07	日本たばこ産業株式会社	５−５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US7309708B2 (en)	2003-11-20	2007-12-18	Birstol-Myers Squibb Company	Hepatitis C virus inhibitors
US7135462B2 (en)	2003-11-20	2006-11-14	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CN1902216A (zh)	2003-11-20	2007-01-24	先灵公司	丙肝病毒ns3蛋白酶的去肽化抑制剂
ES2358333T3 (es)	2004-01-21	2011-05-09	Boehringer Ingelheim International Gmbh	Péptidos macrocíclicos con acción contra el virus de la hepatitis c.
KR20120091276A (ko)	2004-02-20	2012-08-17	베링거 인겔하임 인터내셔날 게엠베하	바이러스 폴리머라제 억제제
EP1763531A4 (en)	2004-06-28	2009-07-01	Boehringer Ingelheim Int	ANALOGUE OF HEPATITIS-C INHIBITING PEPTIDES
PE20060569A1 (es)	2004-07-16	2006-06-22	Boehringer Ingelheim Int	Compuestos de indol carbonilamino como inhibidores de la polimerasa ne5b del vhc
UY29016A1 (es)	2004-07-20	2006-02-24	Boehringer Ingelheim Int	Analogos de dipeptidos inhibidores de la hepatitis c
JP4914355B2 (ja)	2004-07-20	2012-04-11	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃ型肝炎インヒビターペプチド類似体
CA2606195C (en) *	2005-05-02	2015-03-31	Merck And Co., Inc.	Hcv ns3 protease inhibitors
US7470664B2 (en)	2005-07-20	2008-12-30	Merck & Co., Inc.	HCV NS3 protease inhibitors
CN101263156A (zh)	2005-07-25	2008-09-10	因特蒙公司	C型肝炎病毒复制的新颖大环抑制剂
RU2008107972A (ru)	2005-08-01	2009-09-10	Мерк энд Ко., Инк. (US)	Макроциклические пептиды в качестве ингибиторов ns3-протеазы hcv
GB0609492D0 (en)	2006-05-15	2006-06-21	Angeletti P Ist Richerche Bio	Therapeutic agents
GB0612423D0 (en)	2006-06-23	2006-08-02	Angeletti P Ist Richerche Bio	Therapeutic agents
PE20080992A1 (es)	2006-06-26	2008-08-06	Enanta Pharm Inc	Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c
US7635683B2 (en)	2006-08-04	2009-12-22	Enanta Pharmaceuticals, Inc.	Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7582605B2 (en)	2006-08-11	2009-09-01	Enanta Pharmaceuticals, Inc.	Phosphorus-containing hepatitis C serine protease inhibitors
JP5345941B2 (ja)	2006-10-24	2013-11-20	メルク・シャープ・アンド・ドーム・コーポレーション	Ｈｃｖｎｓ３プロテアーゼ阻害剤
WO2008051477A2 (en)	2006-10-24	2008-05-02	Merck & Co., Inc.	Hcv ns3 protease inhibitors
US8138164B2 (en)	2006-10-24	2012-03-20	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
WO2008057208A2 (en)	2006-10-27	2008-05-15	Merck & Co., Inc.	Hcv ns3 protease inhibitors
BRPI0718161A2 (pt)	2006-10-27	2013-11-26	Merck & Co Inc	Composto, composição farmacêutica, e, uso do composto.
US8377872B2 (en)	2007-04-26	2013-02-19	Enanta Pharmaceuticals, Inc.	Cyclic P3 tripeptide hepatitis C serine protease inhibitors
WO2008134397A1 (en)	2007-04-26	2008-11-06	Enanta Pharmaceuticals, Inc.	Aza-tripeptide hepatitis c serine protease inhibitors
US20080267917A1 (en)	2007-04-26	2008-10-30	Deqiang Niu	N-functionalized amides as hepatitis c serine protease inhibitors
US8927569B2 (en)	2007-07-19	2015-01-06	Merck Sharp & Dohme Corp.	Macrocyclic compounds as antiviral agents
US8383583B2 (en)	2007-10-26	2013-02-26	Enanta Pharmaceuticals, Inc.	Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
JP2011503201A (ja)	2007-11-14	2011-01-27	エナンタファーマシューティカルズインコーポレイテッド	大環状テトラゾリルｃ型肝炎セリンプロテアーゼ阻害剤
CL2008003384A1 (es)	2007-11-14	2009-12-11	Enanta Pharm Inc	Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
CA2708042A1 (en)	2007-12-05	2009-06-11	Enanta Pharmaceuticals, Inc.	Quinoxalinyl derivatives
US8940688B2 (en)	2007-12-05	2015-01-27	Enanta Pharmaceuticals, Inc.	Fluorinated tripeptide HCV serine protease inhibitors
WO2009079352A1 (en)	2007-12-14	2009-06-25	Enanta Pharmaceuticals, Inc.	Macrocyclic oximyl hepatitis c serine protease inhibitors
US8273709B2 (en)	2007-12-14	2012-09-25	Enanta Pharmaceuticals, Inc.	Triazole-containing macrocyclic HCV serine protease inhibitors
US8283309B2 (en)	2007-12-20	2012-10-09	Enanta Pharmaceuticals, Inc.	Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
EP2268285B1 (en) *	2008-02-25	2018-06-27	Merck Sharp & Dohme Corp.	Therapeutic compounds
EP2268619A4 (en)	2008-03-20	2012-04-04	Enanta Pharm Inc	FLUORINATED MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
JP2011518882A (ja)	2008-04-28	2011-06-30	メルク・シャープ・エンド・ドーム・コーポレイション	Ｈｃｖｎｓ３プロテアーゼ阻害剤
WO2009134987A1 (en) *	2008-04-30	2009-11-05	Enanta Pharmaceuticals, Inc.	Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
NZ590638A (en)	2008-07-22	2012-06-29	Merck Sharp & Dohme	MACROCYCLIC QUINOXALINE COMPOUNDS AS Hepatitis C Virus NS3 PROTEASE INHIBITORS
MX2011012155A (es)	2009-05-13	2012-02-28	Enanta Pharm Inc	Compuestos macrociclicos como inhibidores del virus de hepatitis c.
EP2459582B1 (en)	2009-07-30	2015-05-27	Merck Sharp & Dohme Corp.	Hepatitis c virus ns3 protease inhibitors
TW201119667A (en)	2009-10-19	2011-06-16	Enanta Pharm Inc	Bismacrocyclic compounds as hepatitis C virus inhibitors
WO2012040040A1 (en)	2010-09-21	2012-03-29	Merck Sharp & Dohme Corp.	Hcv ns3 protease inhibitors
CN104829688B (zh)	2010-09-21	2021-02-09	益安药业	大环脯氨酸衍生的hcv丝氨酸蛋白酶抑制剂

2011
- 2011-09-20 CN CN201510204986.9A patent/CN104829688B/zh active Active
- 2011-09-20 UA UAA201305119A patent/UA116616C2/uk unknown
- 2011-09-20 HU HUE11827336A patent/HUE028384T2/en unknown
- 2011-09-20 KR KR1020197027736A patent/KR102128232B1/ko active IP Right Grant
- 2011-09-20 NZ NZ608720A patent/NZ608720A/en unknown
- 2011-09-20 EA EA201390425A patent/EA023009B1/ru active Protection Beyond IP Right Term
- 2011-09-20 BR BR112013006693-8A patent/BR112013006693B1/pt active IP Right Grant
- 2011-09-20 CR CR20180517A patent/CR20180517A/es unknown
- 2011-09-20 EP EP15202935.1A patent/EP3020723A1/en not_active Withdrawn
- 2011-09-20 KR KR1020197016764A patent/KR102163902B1/ko active IP Right Grant
- 2011-09-20 UY UY0001038339A patent/UY38339A/es not_active Application Discontinuation
- 2011-09-20 PL PL11827336T patent/PL2618831T3/pl unknown
- 2011-09-20 RS RS20160169A patent/RS54638B1/en unknown
- 2011-09-20 AR ARP110103420A patent/AR083052A1/es active IP Right Grant
- 2011-09-20 MX MX2013003230A patent/MX343275B/es active IP Right Grant
- 2011-09-20 SG SG2013020672A patent/SG188618A1/en unknown
- 2011-09-20 KR KR1020187024775A patent/KR101990279B1/ko active IP Right Grant
- 2011-09-20 JP JP2013529408A patent/JP5857053B2/ja active Active
- 2011-09-20 MY MYPI2013700450A patent/MY164754A/en unknown
- 2011-09-20 KR KR1020137010100A patent/KR101894704B1/ko active IP Right Grant
- 2011-09-20 CN CN201180055762.6A patent/CN103209703B/zh active Active
- 2011-09-20 EP EP11827336.6A patent/EP2618831B1/en active Active
- 2011-09-20 KR KR1020207028340A patent/KR20200117065A/ko not_active Application Discontinuation
- 2011-09-20 DK DK11827336.6T patent/DK2618831T3/en active
- 2011-09-20 UY UY0001033617A patent/UY33617A/es active IP Right Grant
- 2011-09-20 ES ES11827336.6T patent/ES2560003T3/es active Active
- 2011-09-20 WO PCT/US2011/052304 patent/WO2012040167A1/en active Application Filing
- 2011-09-20 NZ NZ703416A patent/NZ703416A/en unknown
- 2011-09-20 MX MX2016014229A patent/MX369246B/es unknown
- 2011-09-20 US US13/237,120 patent/US8648037B2/en active Active
- 2011-09-20 CA CA2812261A patent/CA2812261C/en active Active
- 2011-09-20 AU AU2011305695A patent/AU2011305695B2/en active Active
- 2011-09-20 EA EA201500728A patent/EA029145B1/ru active Protection Beyond IP Right Term
- 2011-09-20 TW TW100133824A patent/TWI523658B/zh active
- 2011-09-20 PE PE2013000545A patent/PE20140015A1/es active IP Right Grant
- 2011-09-20 SI SI201130775A patent/SI2618831T1/sl unknown
- 2011-09-20 PT PT118273366T patent/PT2618831E/pt unknown
2013
- 2013-03-21 CR CR20130135A patent/CR20130135A/es unknown
- 2013-03-21 GT GT201300077A patent/GT201300077A/es unknown
- 2013-03-21 CL CL2013000791A patent/CL2013000791A1/es unknown
- 2013-03-21 IL IL225412A patent/IL225412A/en active IP Right Grant
- 2013-03-21 DO DO2013000062A patent/DOP2013000062A/es unknown
- 2013-03-21 MX MX2019013037A patent/MX2019013037A/es unknown
- 2013-03-21 GT GT201300077AA patent/GT201300077AA/es unknown
- 2013-03-21 CO CO13056413A patent/CO6700835A2/es unknown
- 2013-03-27 ZA ZA2013/02317A patent/ZA201302317B/en unknown
- 2013-04-18 EC ECSP13012559 patent/ECSP13012559A/es unknown
- 2013-11-19 ZA ZA2013/08655A patent/ZA201308655B/en unknown
2014
- 2014-01-02 US US14/146,161 patent/US9220748B2/en active Active
- 2014-01-06 HK HK16112273.5A patent/HK1223955A1/zh unknown
- 2014-01-06 HK HK14100080.5A patent/HK1186979A1/zh unknown
- 2014-03-13 CL CL2014000612A patent/CL2014000612A1/es unknown
2015
- 2015-11-20 US US14/946,866 patent/US20160145298A1/en not_active Abandoned
- 2015-12-11 JP JP2015241811A patent/JP6352238B2/ja active Active
2016
- 2016-01-13 CY CY20161100029T patent/CY1117113T1/el unknown
- 2016-01-26 HR HRP20160083TT patent/HRP20160083T1/hr unknown
- 2016-04-11 SM SM201600100T patent/SMT201600100B/xx unknown
- 2016-06-29 AU AU2016204491A patent/AU2016204491A1/en not_active Abandoned
- 2016-10-06 US US15/287,042 patent/US20170088583A1/en not_active Abandoned
2017
- 2017-10-10 LU LU00037C patent/LUC00037I2/fr unknown
- 2017-10-24 LT LTPA2017034C patent/LTC2618831I2/lt unknown
- 2017-10-24 CY CY2017033C patent/CY2017033I1/el unknown
- 2017-10-26 HU HUS1700039C patent/HUS1700039I1/hu unknown
- 2017-10-27 NL NL300900C patent/NL300900I2/nl unknown
- 2017-11-10 NO NO2017056C patent/NO2017056I2/no unknown
- 2017-12-12 US US15/839,249 patent/US20180162905A1/en not_active Abandoned
2018
- 2018-06-05 JP JP2018107455A patent/JP6574023B2/ja active Active
- 2018-09-26 US US16/142,087 patent/US20190263860A1/en not_active Abandoned
2019
- 2019-08-13 JP JP2019148420A patent/JP2020015730A/ja active Pending
- 2019-08-21 DO DO2019000218A patent/DOP2019000218A/es unknown
- 2019-10-04 EC ECSENADI201972215A patent/ECSP19072215A/es unknown
- 2019-12-23 US US16/724,677 patent/US20200270303A1/en not_active Abandoned
2021
- 2021-01-15 JP JP2021004680A patent/JP2021063130A/ja not_active Ceased
- 2021-09-16 NO NO2021040C patent/NO2021040I1/no unknown

Also Published As

Publication number	Publication date
JP5857053B2 (ja)	2016-02-10
AR083052A1 (es)	2013-01-30
AU2011305695B2 (en)	2016-05-19
ZA201302317B (en)	2014-09-25
NZ608720A (en)	2015-03-27
NO2017056I1 (no)	2017-11-10
US20190263860A1 (en)	2019-08-29
MY164754A (en)	2018-01-30
DOP2013000062A (es)	2013-07-15
EA201390425A1 (ru)	2013-09-30
TWI523658B (zh)	2016-03-01
CA2812261A1 (en)	2012-03-29
CR20130135A (es)	2013-10-04
CY1117113T1 (el)	2017-04-05
KR20180099929A (ko)	2018-09-05
AU2011305695A1 (en)	2013-04-11
US20160145298A1 (en)	2016-05-26
KR20200117065A (ko)	2020-10-13
HUS1700039I1 (hu)	2017-11-28
EP3020723A1 (en)	2016-05-18
NL300900I2 (nl)	2017-11-16
JP2016104756A (ja)	2016-06-09
JP2021063130A (ja)	2021-04-22
JP2018162265A (ja)	2018-10-18
JP6574023B2 (ja)	2019-09-11
HK1223955A1 (zh)	2017-08-11
ES2560003T3 (es)	2016-02-17
CY2017033I2 (el)	2018-04-04
ECSP13012559A (es)	2014-05-31
EP2618831A1 (en)	2013-07-31
MX369246B (es)	2019-11-01
WO2012040167A1 (en)	2012-03-29
NO2021040I1 (no)	2021-09-16
PE20140015A1 (es)	2014-02-16
CO6700835A2 (es)	2013-06-28
EA201500728A2 (ru)	2016-03-31
GT201300077A (es)	2014-12-16
US20170088583A1 (en)	2017-03-30
CN104829688B (zh)	2021-02-09
LUC00037I2 (no)	2017-12-13
SMT201600100B (it)	2016-04-29
US20200270303A1 (en)	2020-08-27
US9220748B2 (en)	2015-12-29
KR20190110648A (ko)	2019-09-30
UY33617A (es)	2012-07-31
CA2812261C (en)	2017-02-21
EP2618831B1 (en)	2016-01-06
US8648037B2 (en)	2014-02-11
MX343275B (es)	2016-10-31
US20120070416A1 (en)	2012-03-22
KR102163902B1 (ko)	2020-10-12
LTPA2017034I1 (lt)	2017-11-10
KR102128232B1 (ko)	2020-06-30
MX2019013037A (es)	2020-02-05
SG188618A1 (en)	2013-04-30
SI2618831T1 (sl)	2016-06-30
MX2013003230A (es)	2013-10-17
CL2014000612A1 (es)	2014-09-05
EA023009B1 (ru)	2016-04-29
EA201500728A3 (ru)	2016-07-29
CR20180517A (es)	2018-12-06
CN104829688A (zh)	2015-08-12
RS54638B1 (en)	2016-08-31
JP6352238B2 (ja)	2018-07-04
PT2618831E (pt)	2016-03-04
IL225412A0 (en)	2013-06-27
CN103209703A (zh)	2013-07-17
KR101894704B1 (ko)	2018-09-05
TW201216979A (en)	2012-05-01
IL225412A (en)	2017-02-28
BR112013006693B1 (pt)	2022-07-12
ECSP19072215A (es)	2019-10-31
DK2618831T3 (en)	2016-04-04
US20180162905A1 (en)	2018-06-14
HRP20160083T1 (hr)	2016-02-26
US20140194350A1 (en)	2014-07-10
KR20130098369A (ko)	2013-09-04
LTC2618831I2 (lt)	2021-11-10
CL2013000791A1 (es)	2013-07-12
KR20190069623A (ko)	2019-06-19
KR101990279B1 (ko)	2019-06-19
PL2618831T3 (pl)	2016-06-30
CN103209703B (zh)	2015-05-27
ZA201308655B (en)	2014-11-26
CY2017033I1 (el)	2018-04-04
HUE028384T2 (en)	2016-12-28
JP2020015730A (ja)	2020-01-30
BR112013006693A2 (pt)	2016-06-14
NZ703416A (en)	2016-06-24
DOP2019000218A (es)	2019-09-15
EA029145B1 (ru)	2018-02-28
GT201300077AA (es)	2019-11-13
UA116616C2 (uk)	2018-04-25
JP2013538235A (ja)	2013-10-10
UY38339A (es)	2020-12-31
AU2016204491A1 (en)	2016-07-21
EP2618831A4 (en)	2014-11-19
LUC00037I1 (no)	2017-10-12
HK1186979A1 (zh)	2014-03-28

Publication	Publication Date	Title
NO2017056I2 (no)	2018-11-26	glekaprevir eller et farmasøytisk akseptabelt salt eller en ester derav
NO2020047I1 (no)	2020-12-23	Remdesivir eller et farmasøytisk akseptabelt salt eller ester derav
NO2021033I1 (no)	2021-09-06	Selineksor eller et farmasøytisk akseptabelt salt derav
NO2017057I1 (no)	2017-11-10	pibrentasvir eller et farmasøytisk akseptabelt salt derav
NO2019019I1 (no)	2019-04-24	Doravirin eller et farmasøytisk akseptabelt salt derav
NO2023040I1 (no)	2023-10-20	Atogepant or a pharmaceutically acceptable salt thereof
NO2019012I1 (no)	2019-03-05	Enkorafenib eller et farmasøytisk akseptabelt salt eller solvat derav
NO2020037I1 (no)	2020-11-16	alpelisib eller et farmasøytisk akseptabelt salt derav
NO2021034I1 (no)	2021-09-09	pemigatinib or a pharmaceutically acceptable salt thereof
NO2020018I1 (no)	2020-06-17	Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof
NO2019024I1 (no)	2019-05-20	Brigatinib eller et farmasøytisk akseptabelt salt derav
NL301157I2 (nl)	2023-11-09	odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NO2022044I1 (no)	2022-10-27	daridorexant eller et farmasøytisk akseptabelt salt derav, spesielt daridorexant hydroklorid
NO2021041I1 (no)	2021-09-20	remimazolam or a pharmaceutically acceptable salt thereof
NO2022031I1 (no)	2022-07-20	Voxelotor or a tautomer or pharmaceutically acceptable salt thereof
FIC20230028I1 (fi)	2023-08-28	Deukravasitinibi tai sen framaseuttisesti hyväksyttävä suola
FIC20240012I1 (fi)	2024-04-18	Omaveloksoloni tai sen farmaseuttisesti hyväksyttävä suola
NO2022033I1 (no)	2022-07-22	Rimegepant or a pharmaceutically acceptable salt thereof
NO2020006I1 (no)	2020-03-11	upadacitinib or a pharmaceutically acceptable salt thereof
NO2017059I1 (no)	2017-11-13	ribosiklib eller et farmasøytisk akseptabelt salt derav
NO2018026I2 (no)	2018-08-23	Bictegravir eller et farmasøytisk akseptabelt salt derav, spesielt natriumbictegravir
NO2019008I1 (no)	2019-02-19	Allopurinol/lesinurad eller et farmasøytisk aksepterbart salt eller salter derav
FIC20240022I1 (fi)	2024-06-19	Retsafungiini tai sen farmaseuttisesti hyväksyttävä suola, erityisesti retsafungiiniasetaatti
NO2015014I1 (no)	2015-05-04	Paritaprevir, eller et farmasøytisk akseptabelt salt eller ester derav
NO2015012I2 (no)	2015-04-22	Ombitasvir, eller et farmasøytisk akseptabelt salt derav